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ABSTRACT
The Gene Expression Atlas (http://www.ebi.ac
.uk/gxa) is an added-value database providing infor-
mation about gene expression in different cell types,
organism parts, developmental stages, disease
states, sample treatments and other biological/
experimental conditions. The content of this
database derives from curation, re-annotation and
statistical analysis of selected data from the
ArrayExpress Archive of Functional Genomics
Data. A simple interface allows the user to query
for differential gene expression either (i) by gene
names or attributes such as Gene Ontology terms,
or (ii) by biological conditions, e.g. diseases,
organism parts or cell types. The gene queries
return the conditions where expression has been
reported, while condition queries return which
genes are reported to be expressed in these
conditions. A combination of both query types is
possible. The query results are ranked using
various statistical measures and by how many inde-
pendent studies in the database show the particular
gene-condition association. Currently, the database
contains information about more than 200000 genes
from nine species and almost 4500 biological
conditions studied in over 30000 assays from over
1000 independent studies.
INTRODUCTION
In the last decade, genome-wide gene expression assays,
mostly employing microarrays and more recently high-
throughput sequencing, have become common tools in
biomedical and biological research. Most assays are per-
formed to answer speciﬁc questions, for instance, to ﬁnd
which genes are diﬀerentially expressed in a particular
disease state in comparison with healthy condition in a
tissue or cell type. Some experiments instead compare
a larger number of conditions, such as various tissue or
cell types, i.e. the well known and widely used Genomics
Institute of the Novartis Research Foundation gene
expression atlas dataset for human and mouse (1).
Expression datasets derived from high-throughput
experiments have utility beyond answering the speciﬁc
questions that have been posed in the original experiments
generating them. For instance, if a gene expression study
has revealed a set of genes diﬀerentially expressed in
a particular disease, making this information available
online may help others working on the same disease, it
can help in selecting candidate genes, or prioritizing the
existing ones.
In compliance with the MIAME initiative (2), most
scientiﬁc journals nowadays require publication-related
microarray gene expression data to be deposited in
public repositories like ArrayExpress (3) or the Gene
Expression Omnibus (GEO) (4). Data from over 10000
independent studies are readily available from these
archives in several formats; however, using these deposited
data to answer biological questions is not straight-
forward. For instance, to ﬁnd which genes are
diﬀerentially expressed in a particular disease eﬀectively
one would need to download the datasets relevant to
this disease and re-analyse them. Secondary databases,
such as Oncomine (5) or Genevestigator (6), are doing
the work of importing speciﬁc datasets from the public
archives, re-analysing and making them available
through various interfaces. Most of these databases are
speciﬁc to particular biological domains and are, at least
in part, commercial. The GEO proﬁles service is providing
gene-based queries for expression proﬁles, however, it
does not allow searches for genes speciﬁc to a particular
condition (e.g. a particular disease or tissue), nor for
conditions speciﬁc to a particular gene.
The European Bioinformatics Institute (EBI) has
launched a new database called the Gene Expression
Atlas that allows users to query gene expression under
various biological conditions, including diﬀerent cell
*To whom correspondence should be addressed. Tel: +44 1223 494 647; Fax: +44 1223 494 468; Email: ostolop@ebi.ac.uk
D690–D698 Nucleic Acids Research, 2010, Vol. 38, Database issue Published online 11 November 2009
doi:10.1093/nar/gkp936
 The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.types, developmental stages, physiological states, pheno-
types and disease states. The key questions this new
resource can answer can be summarized as:
(i) Under which conditions or where in the organism is
a gene of interest diﬀerentially expressed?
(ii) Whichgenesarediﬀerentially expressedinacondition
or site (for instance in a disease, or in an organ)?
Both the questions can also be combined to focus on par-
ticular genes and their role in a speciﬁc disease, such as
identifying members of the Wnt signalling pathway, which
are expressed in a speciﬁc type of cancer.
The Atlas takes data directly from the ArrayExpress
Archive of Functional Genomics Experiments, including
data imported from GEO (4). The selected datasets are
then systematically curated, genes are mapped to the
latest genome builds and the experimental conditions are
systematized and mapped to an application ontology, the
Experimental Factor Ontology (EFO) (7). Statistical
computations are performed, providing P-values linking
each gene to each experimental condition in every study. A
simple query interface is implemented, and the results are
ranked by their P-values and weighted by the number of
independent studies linking genes to biological conditions.
The advanced interface enables the user to ask more
sophisticated questions; tutorial materials are available
at http://www.ebi.ac.uk/microarray-srv/tutorials.
The EBI Gene Expression Atlas freely provides its
content for online queries and for programmatic access
without restriction and without requirement to register.
The complete content will be made available for
download following the publication of this article.
As of August 2009, the EBI’s Gene Expression Atlas
contains data for over 200000 genes from over 1000 dif-
ferent independent studies, including more than 30000
samples representing nearly 4500 diﬀerent biological
conditions. Nine diﬀerent species, including human and
model organisms, are included. The database is updated
monthly, and is growing constantly. With streamlining of




The Gene Expression Atlas interface (Figure 1) allows the
user to query for condition-speciﬁc gene expression across
multiple datasets. There are three basic types of queries:
(i) for a gene, or a set of genes, by name or various gene
attributes, including synonyms, Ensembl identiﬁers and
Gene Ontology terms; (ii) for a ‘biological condition’,
such as, disease name, developmental stage, as well as
tissue or cell type; and (iii) for a combination of genes
and biological conditions. Biological conditions, also
referred to as EFs, are organized using an application
ontology called EFO, which is described in more detail
in the next section.
If a query matches one gene uniquely, the ‘Gene page’
for that gene is displayed (Figure 2). This page
summarizes the behaviour of the selected gene across all
Atlas datasets, providing easy access to both statistical
analysis results and expression data. All gene pages can
be linked directly, using links of the form http://www.ebi
.ac.uk/gxa/gene/IDENTIFIER, where IDENTIFIER is
any one of annotated gene attributes (e.g. Ensembl,
UniProt and other accessions). Direct links can also be
made to Atlas experiments, e.g. http://www.ebi.ac
.uk/gxa/experiment/E-AFMX-5. Full details for linking
and other Atlas use are available in online Atlas
documentation.
The thumbnail plots provide a direct link to individual
experiment pages where the gene expression proﬁle for the
selected gene can be viewed in detail (Figure 3). In the
experimental page, multiple ‘search’ options allow the
user to retrieve genes of interest and add their expression
proﬁles to the main plot (Figure 3, right). The search
options available are: (i) search for any gene by name or
attribute; (ii) search up to 10 most similar genes, based
on Pearson correlation, to any of the genes currently
plotted; and (iii) choose any gene from a list of top
10 diﬀerentially expressed genes for the selected study.
For each gene, a P-value of signiﬁcance of diﬀerential
expression is provided.
It is also possible to query for such a condition as a
particular disease, either over all genes or for those
matching speciﬁed attributes, such as belonging to a
pathway. Figure 4 is an example of a summary view of
transcriptional activity among members of the ‘Wnt sig-
nalling pathway’ in ‘carcinoma’. Both ‘Genes’ and
‘Conditions’ boxes provide auto complete functionality
to help the user formulate queries. Condition queries
(Figure 4, top) are expanded using our application
ontology (EFO, see next section) to include all child
terms available for the original query, so that, for
Figure 1. Gene Expression Atlas home page. Querying for gene(s) will identify all genes whose annotation matches your query. The ‘Conditions’
parameter will identify all experiments in which the conditions that match your query appear. Searches can be restricted only to genes belonging to a
given organism and also by direction of diﬀerential expression.
Nucleic Acids Research, 2010,Vol.38, Database issue D691instance, brain queries are expanded to all brain parts. The
query results are displayed as a heat map (Figure 4,
middle); genes matching the query are listed in the ﬁrst
column and the conditions go across the remaining
columns grouped under ‘Ontology’ (when the query
matches an ontology term) and ‘Keywords’ (when the
query matches a keyword). All conditions mapping to
Ontology terms are shown as nodes in the EFO tree
(Figure 4, bottom; see next section). As in the ‘gene
page’, the red colour corresponds to up-regulation of the
selected gene in the selected condition, and the blue
corresponds to down-regulation. The numbers in the cell
correspond to the number of independent studies where
diﬀerential expression has been observed, and the colour
intensity represents the best P-value of this observation
(i.e. the brighter the colour, the more signiﬁcant the
P-value). Results can be downloaded in tab-delimited
format. Clicking on a cell in the heat map opens a
window, showing information about the expression of
the selected gene in the associated experiments including
thumbnail plots of the gene expression proﬁle(s) and links
to the experimental details in the ArrayExpress Archive of
Functional Genomics Data, as shown in Figure 2.
A query can be reﬁned by using terms enriched in the
results (‘reﬁne your query’ link; Figure 4, middle), by
adding conditions to the original query (using the
‘advanced search’ link), as well as by adding various
ﬁlters through the advanced interface, which allows user
to formulate complex queries by combining several
conditions, gene property and organism ﬁlters in one
query.
Biological conditions—the concepts of EFs and
their values
High-throughput gene expression experiments are typi-
cally used to compare gene expression in diﬀerent biolog-
ical conditions. Our approach to describe biological
conditions is based on the concept of EF and EF value
(EFV). An EF is deﬁned as the experimental variable that
is tested for gene expression variation, and EFVs are the
values of this variable. For instance, in an experiment that
compares gene expression in leukemic to normal blood,
EF is a disease state, which has two values, leukemia and
normal.
Figure 2. ‘Gene page’ for Mus musculus Saa4. The following information is displayed: (A) summary of terms and external databases cross-references,
as well as orthologue genes, which allows comparison of orthologues across the Atlas; (B) expression heat map listing all the conditions in which the
gene was observed diﬀerentially expressed. The heatmap cell colour ranges from red, i.e. up-regulated, to blue, i.e. down-regulated. For each
condition, the number of independent studies in which the gene was observed signiﬁcantly up- or down-regulated is provided. Saa4 is over-expressed
in ‘liver’, in 16 independent studies, which is consistent with the notion that liver is the primary site of Saa4 mRNA transcription (8) and (C)
thumbnail plots of gene expression proﬁles for the studies in which the gene was found to be diﬀerentially expressed. Saa4 shows the highest
signiﬁcance of diﬀerential expression in the experiment E-MEXP-1190, comparing kidney, liver and spleen, each assayed in several replicates. A link
to the experimental details in the ArrayExpress Archive of Functional Genomics Data is provided for each experiment.
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at least one deﬁned EF with at least two diﬀerent EFVs,
and each EFV should be tested in at least two replicates.
Experiments can have multiple EFs, for instance normal
and leukemic gene expression can be proﬁled in peripheral
blood or bone marrow. Such an experiment has two EFs,
disease state and organism part.
Using free text keywords to describe EFs and their
values limits their utility. For instance, to identify genes
diﬀerentially expressed in ‘cancer’, we would also like to
ﬁnd genes that are studied in an experiment proﬁling
‘leukemia’. One way to achieve this is to use a disease
ontology linking ‘leukemia’ to ‘cancer’ as a type of
cancer, and then expand the query to all cancer types.
Since in Gene Expression Atlas we are dealing with EFs
mapping to a wide range of biological concepts such
as organism parts, diseases or treatments, we require
multiple source ontologies to describe these conditions.
Initial mapping to existing ontologies identiﬁed the NCI
Thesaurus (9) as providing best coverage due to the large
amount of gene expression data performed on cancer
samples. However, as no external ontology covered all
our EFs and EFVs, we developed our own application
ontology called EFO (7).
Mappings from EFO to external ontologies are main-
tained as identiﬁers from the external resource into
a ‘denition citation’ annotation property in EFO.
Equivalent classes are thus mapped from EFO into
multiple other ontologies, for example a ‘neoplasia’
in EFO maps to ‘neoplasia’ in the NCI Thesaurus (9).
This appears in the EFO ‘denition citation’ property,
which has the value ‘NCI Thesaurus:C3262’. Typically,
there are multiple maps to external ontologies as many
biomedical ontologies and controlled vocabularies are
non-orthogonal. EFO is released synchronously with
the Atlas, new terms being added to each release where
needed to describe Atlas data. EFO is mapped to 14
external ontologies including the NCI Thesaurus, the
Foundational Model of Anatomy (10) and Chemical
Entities of Biological Interest (ChEBI) (11) (for full list
see http://www.ebi.ac.uk/efo/overview). As illustrated in
the previous section, EFO is used in the Atlas to expand
queries as outlined above, as well as a means to browse the
Atlas content.
Where datasets are submitted directly to ArrayExpress,
the submission tools guide the users through annotation
of their EF and EFV, which later are checked and curated
by the ArrayExpress staﬀ. For data imported into
ArrayExpress from GEO, we use text mining tools using
EFO as the dictionary to identify the potential EFs and
EFVs, and then introduce them via curation.
Statistical computations to rank query results
The meta-analysis approach taken in the construction
of the Atlas can be outlined as follows. For each
experiment:
(i) identify diﬀerentially expressed genes for each EF;
(ii) for each gene found, identify EFVs where the gene’s
mean expression level is signiﬁcantly diﬀerent from
its overall mean across all factor values; and
Figure 3. Gene expression proﬁle page for experiment E-MEXP-1190 showing the table of genes with similar expression proﬁle to Saa4, identiﬁed
through similarity search. In the main graph, the horizontal axis shows all samples in this experiment, grouped by EF. The vertical axis shows the
expression levels for Saa4 in each sample. The EF ‘organism part’ is selected and, under this condition, Saa4 has notably higher expression values in
liver, as expected. Sample attributes can be selected from the ‘Sample attributes’ table and highlighted on the graph.
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aggregate the identiﬁed Gene-EFV associations for
storage and retrieval.
If an experiment has several factors, i.e. a multi-
factorial experiment design, we treat each factor
independently from all others, and identify Gene–EFV
associations separately for each EF in an experiment.
This represents a simpliﬁcation, and assumes that there
are no interactions between EFs (see ‘Discussion’
section). We observed that in most cases (data not
shown) of multi-factorial experiment designs, even if the
factors are treated independently, once one statistically
signiﬁcant factor is identiﬁed for a gene, secondary
factors’ eﬀects become readily visible to the investigator
when visualizing the data. For this reason, to construct a
basic platform for further data analysis, we initially
limited statistical analysis to the factor independence
scenario.
The detailed description of the data analysis procedure
outline is below:
(i) If ygj are expression values for genes g ¼ 1,...,G
and arrays j ¼ 1,...,J, pre-processed, background-
corrected and normalized, we describe systematic
expression eﬀects for each gene by a linear model
Ey g

¼ Xg, where yg ¼ð yg1,...,ygJÞ
T is the
vector of expression values for gene g, X is a
known design matrix with full column rank K
and g ¼ g1,...,gK
 T is a gene-speciﬁc vector of
regression coeﬃcients. The design matrix depends
on the experimental design and choice of
Figure 4. Query results for human genes matching GO term ‘Wnt signaling pathway’ expressed in condition ‘carcinoma’. The ‘conditions’ auto
complete function uses the EFO controlled vocabulary to expand queries, to query synonyms and to suggest query terms (top). In this example,
SOX4 gene is over-expressed in adenocarcinoma in three diﬀerent independent studies. Results are split over several pages and can be downloaded
using the link provided (middle). Advanced query functionality is accessed using the ‘advanced search’ link below the ‘Search Atlas’ button.
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represent comparisons of interest between RNA
sources in the experiment. These coeﬃcients are
estimated with a least squares linear model ﬁtting
procedure in the Bioconductor package limma (12)
and tested for diﬀerential expression (i.e. testing any
particular gk equal to 0) with moderated Student’s
t-statistic via the empirical Bayesian statistics
developed by Smyth (12). For each EF in the exper-
iment, we set up a complete pairwise-comparisons
contrast matrix (equivalent to one-way Analysis of
Variance) as an omnibus test of diﬀerential expres-
sion across all factor values in the selected factor.
We then can accept or reject the ‘equal means for all
groups’ null hypothesis on the basis of P-values
computed for the omnibus F-statistic via limma as
described above, at a speciﬁed signiﬁcance level.
These P-values, with appropriate multiple testing
adjustment to control the False Discovery Rate
(FDR) at 5% (13), allow us to identify diﬀerentially
expressed genes.
(ii) Given a set of expression values for a gene under
k diﬀerent conditions, hence k group means
g1,...,gk and a signiﬁcant F-statistic, we look at
k diﬀerences      i, of each group mean to the
global mean, and seek to identify which ones are
signiﬁcant, and in what direction. The problem
of multiple comparisons with the overall mean
is known in statistical literature as an Multiple
Comparisons with the Mean procedure. We
follow Hsu (14) to make direct inference on
multiple comparisons of the means. For each gene
we compute k simultaneous conﬁdence intervals
governed by a multivariate t-distribution and
computed from quantiles of the Studentized
maximum modulus statistic and look at their
directionality.
(iii) Steps (i) and (ii) for each factor in a given experi-
ment produce a matrix of up/down calls ( 1, 0 or 1)
according to the directionality of the conﬁdence
interval and respective P-values: one call/P-value
for each Gene–EFV combination. Multiple testing
adjustment is performed on these P-values to
control the global (across genes and contrasts, i.e.
EFVs) FDR at 5%, following recommendations
by Smyth in limma (12). Taking advantage of
the robustness of the tests performed, we use the
P-values signiﬁcance-based calls to aggregate diﬀer-
ential expression results into ‘votes’: each time a
gene has been observed as diﬀerentially expressed
in a particular EFV, we use that as a vote for
up/down activity for that Gene–EFV combination.
These are the numbers displayed in the heatmap
view of the Gene Expression Atlas. All the
P-values and computed statistics as well as the
aggregated votes are stored in a database and
indexed for fast retrieval in the interface.
Currently, all data included in the Atlas are based on
microarray assays. The statistical method and the data
integration framework developed are generic and can be
extended to many other technologies, such as RNA-seq
and in situ hybridizations. The R-code for this procedure
is available as Supplementary Data and will be released as
a separate Bioconductor package (in preparation).
Gene expression data
Data for the Atlas are selected from ArrayExpress Archive
and selection is based on various criteria outlined earlier.
As currently we are using only microarray data, our ﬁrst
consideration is whether suﬃcient array annotation is
given to enable us to map the array design elements to
existing gene identiﬁers. We use two routes for this
mapping: we preferentially map array probe sequences
to Ensembl genomes (15) or we attempt to map the
design element annotation identiﬁers to gene annotation
in UniProt database (16). Where re-annotation fails,
experiments that are performed on such arrays cannot
be included in the Atlas. The array re-annotation
pipeline will be released as a software package, described
and published separately (Sarkans et al., in preparation).
Experiments in ArrayExpress Archive that are per-
formed on well-annotated arrays, which have high
MIAME scores (2,17), where the EF/EFV annotation
and suﬃcient replication criteria (as well as some
other technical criteria not described here), and where
normalized data are present, are annotated as ‘suitable
for Atlas’. When all basic criteria are satisﬁed, experiment
selection for the Atlas is motivated by the quality of anno-
tation, use of standard platforms and large sample sizes,
without any preference for any biological conditions.
Recently, we started to produce themed Atlas data
releases, e.g. species oriented or addressing a speciﬁc
research domain, or by curating user-requested studies.
Experiments selected for Atlas are then exported
from the Archive. The submitter’s normalized data are
used, hence we do not perform any renormalization.
Prior to loading into the Atlas, annotations are
harmonized, experimental descriptions checked for con-
sistency and non-standard terms are standardized. Maps
to EFO are added where the term required is present in
the ontology. If terms are not in EFO, we examine
source ontologies and provide a term name, deﬁnition
and maps to external ontologies. The term is then placed
in the EFO hierarchy that is optimized for the Atlas
visualization.
Once data are loaded, statistical computations, as
described in the previous section, are performed and for
each new experiment, for each EF and EFV, for each gene
the P-value is computed.
Currently, the Atlas contains data from nine species.
Table 1 shows the number of assays and the number of
studies (experiments) included from each. The experiments
included in the Atlas together have more than 40 diﬀerent
EFs, covering over 4500 diﬀerent EFVs. The distribution
of the number of assays for the most frequently studied
(at least 50 experiments for each factor) EFs and EFVs are
given in Table 2.
The method used in Gene Expression Atlas analytics
allows us to examine trends in diﬀerential gene expression
across all Atlas data. Figure 5A shows the distribution of
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experiments. There are approximately 400 experiments
(from over 1000) with fewer than 10% of all genes
showing diﬀerential expression; the mean proportion of
genes diﬀerentially expressed in an experiment, according
to our FDR criteria, is 25%. Further, when we examine
the number of diﬀerentially expressed genes per factor
(Figure 5B), we observe that the numbers are highest in
the factors ‘observation’, ‘histology’, ‘cell line’, ‘genera-
tion’ and ‘organism part’. It appears that, broadly,
across species, transcriptional activity is strongly driven
by its context: by tissue (‘histology’, ‘organism part’ and,
by extension, ‘cell line’), followed by developmental stage
and then cell type, while the main extrinsic drivers of
transcriptional activity such as xenobiotic responses
(‘compound treatment’) and disease states contribute to
diﬀerential expression to a smaller extent. We can also
observe that the number of diﬀerentially expressed genes
is largely independent of the number of EFVs (the median
factor value count is around 3 EFVs).
Programmatic access
REST (Representational State Transfer) is a simple tech-
nology that allows users to retrieve data in an easy-to-
parse format by going directly to a web address
Universal Resource Identiﬁer (URI). For instance,
all information available on gene matching ‘aspm’
anywhere in gene property ﬁelds can be obtained by
entering a URI: http://www.ebi.ac.uk/gxa/api?geneIs=
aspm.
This will produce a simple output either in JSON or
XML format (the latter will be used if ‘&format=xml’
is appended to the URI). Example programmatic queries
are provided in Table 3 below.
These APIs allow advanced users to search and retrieve
complete information on any gene or experiment from the
Atlas, including all gene and sample attributes, details of
experimental design, meta-analysis statistics and gene
expression values. Additionally, the Atlas provides a
gene view-based Distributed Annotation System (18)
track at http://www.ebi.ac.uk/gxa/das that can be viewed
with any Distributed Annotation System client such as the
Ensembl genome browser.
Examples of output for these queries are available
from the Atlas documentation at http://www.ebi.ac
.uk/gxa/help/AtlasApis.
DISCUSSION
More than 60% of the experiments in the Atlas have two
or three EFs; our current assumption that they are
Figure 5. Distributions of diﬀerentially expressed genes over (A) experiments and (B) EFs. Error bars in (B) mark the 25% and 75% quantiles in the
diﬀerentially expressed gene count for each EF.
Table 1. Number of studies and assays for each species in the Atlas
Species Assays Studies
Homo sapiens 13703 410
Mus musculus 7539 373
Rattus norvegicus 4858 133
Arabidopsis thaliana 1607 88
Saccharomyces cerevisiae 813 43
Drosophila melanogaster 790 40
Schizosaccharomyces pombe 458 19
Danio rerio 214 13
Caenorhabditis elegans 166 5
Total 30148 1124
Table 2. Most frequently used EFs and the number of EFVs and
studies for each factor
EFs EFVs Studies
Genotype 389 211
Compound treatment 425 196
Disease state 214 137
Organism part 267 98
Cell type 164 61
Growth condition 122 61
Strain or line 227 51
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potential EF interactions is to introduce a single ‘meta-
factor’, with values made of all occurring combinations
of the individual factor values in the comprising factors.
We are currently investigating this and related methods.
In the presented implementation, the experiments are
ranked by a simple ‘vote-counting’ method, ﬁrst described
by Light and Smith (19). It has several known deﬁciencies,
for instance, it does not incorporate the sample size into
the vote, is imprecise, and occasionally has low statistical
power. We are working on employing a more statistically
robust procedure for meta-analysis of P-values derived
from individual diﬀerential expression tests. Using
earlier work by Hedges and Olkin (20) and making use
of the semantic enrichment provided by EFO curation, we
have developed a new eﬀect-size estimation-based method
for data integration, which will be incorporated in the
future Atlas releases.
Currently the Atlas provides information on expression
of only protein-coding genes. In the near future we will
also plan to include data on known micro-RNA expres-
sion. It is possible to deal with the expression of alterna-
tive splice variants, or with expression at the exonic level
using the same methodology. At the moment, all
data included in the Atlas are derived from microarray-
based assays. In the future, as ultra high-throughput
sequencing becomes widespread and we plan to include
RNA-seq and related data types. Presently, the number
of RNA-seq experiments that focus on assaying expres-
sion of known genes and for which the processed data are
available is still relatively small.
Among the new features under development are
graphical gene expression query and display based on
anatomograms. Another improvement will be a possibility
to query and visualize the results by ontology terms of the
user’s choice, not just EFO. We are also building an Atlas
of ‘normal gene expression’, i.e. the gene expression in
diﬀerent organism parts under ‘normal’, non-diseased
conditions.
The code will be released as open source with installa-
tion and data-loading procedures, allowing the users to
run the Atlas locally and use it with their own data.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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